MA26510A1 - PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN SENSITIZER AND AN ANTIHYPERGLYCEMIC AGENT FOR A METHOD OF TREATING DIABETES - Google Patents

PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN SENSITIZER AND AN ANTIHYPERGLYCEMIC AGENT FOR A METHOD OF TREATING DIABETES

Info

Publication number
MA26510A1
MA26510A1 MA25121A MA25121A MA26510A1 MA 26510 A1 MA26510 A1 MA 26510A1 MA 25121 A MA25121 A MA 25121A MA 25121 A MA25121 A MA 25121A MA 26510 A1 MA26510 A1 MA 26510A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
treating diabetes
insulin sensitizer
antihyperglycemic agent
antihyperglycemic
Prior art date
Application number
MA25121A
Other languages
French (fr)
Inventor
Dr Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA26510A1 publication Critical patent/MA26510A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fodder In General (AREA)
MA25121A 1997-06-18 1998-06-17 PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN SENSITIZER AND AN ANTIHYPERGLYCEMIC AGENT FOR A METHOD OF TREATING DIABETES MA26510A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
MA26510A1 true MA26510A1 (en) 2004-12-20

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25121A MA26510A1 (en) 1997-06-18 1998-06-17 PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN SENSITIZER AND AN ANTIHYPERGLYCEMIC AGENT FOR A METHOD OF TREATING DIABETES

Country Status (24)

Country Link
EP (1) EP0975343A1 (en)
JP (1) JP2001523271A (en)
KR (1) KR20010013845A (en)
CN (1) CN1274282A (en)
AP (1) AP9901720A0 (en)
AR (2) AR013352A1 (en)
AU (1) AU8799998A (en)
BG (1) BG103966A (en)
BR (1) BR9810186A (en)
CA (1) CA2294134A1 (en)
CO (1) CO4940453A1 (en)
DZ (1) DZ2519A1 (en)
EA (1) EA200000040A1 (en)
IL (1) IL133138A0 (en)
MA (1) MA26510A1 (en)
NO (1) NO996270L (en)
NZ (1) NZ501345A (en)
OA (1) OA11631A (en)
PE (1) PE89199A1 (en)
PL (1) PL337577A1 (en)
SK (1) SK179499A3 (en)
TR (1) TR199903072T2 (en)
UY (1) UY25051A1 (en)
WO (1) WO1998057635A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103061T2 (en) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. New pharmaceutical ingredient.
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
JP4590158B2 (en) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Combination therapy comprising a glucose reabsorption inhibitor and a retinoid-X receptor modulator
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
JP2004067575A (en) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd Promoter for effect of therapeutic agent for diabetes
CN101121004B (en) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 Medicine composition containing insulin intensifier and miglitol
CN101584705B (en) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 Medicament composition for treating diabetes and complications of diabetes
CN101584688B (en) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 Medicament composition for treating diabetes and complications of diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
AU8799998A (en) 1999-01-04
WO1998057635A1 (en) 1998-12-23
AR014881A1 (en) 2001-04-11
JP2001523271A (en) 2001-11-20
IL133138A0 (en) 2001-03-19
BR9810186A (en) 2000-08-08
UY25051A1 (en) 2000-09-29
EP0975343A1 (en) 2000-02-02
CN1274282A (en) 2000-11-22
PE89199A1 (en) 1999-10-23
NO996270D0 (en) 1999-12-17
NO996270L (en) 1999-12-17
CA2294134A1 (en) 1998-12-23
AR013352A1 (en) 2000-12-27
OA11631A (en) 2004-11-22
BG103966A (en) 2000-07-31
KR20010013845A (en) 2001-02-26
TR199903072T2 (en) 2000-07-21
NZ501345A (en) 2001-10-26
PL337577A1 (en) 2000-08-28
CO4940453A1 (en) 2000-07-24
AP9901720A0 (en) 1999-12-31
SK179499A3 (en) 2000-11-07
DZ2519A1 (en) 2003-02-01
EA200000040A1 (en) 2000-08-28

Similar Documents

Publication Publication Date Title
NL300432I2 (en) Pharmaceutical composition comprising pioglitazoneand glimepiride for use in treatment of diabetes.
MA26510A1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN SENSITIZER AND AN ANTIHYPERGLYCEMIC AGENT FOR A METHOD OF TREATING DIABETES
MX9802130A (en) SELECTIVE 'beta'3 ADRENERGIC AGONISTS.
EA200000041A1 (en) METHOD OF TREATMENT OF DIABETES THIAZOLIDINDIONE AND METHORMIN
DZ2539A1 (en) Pharmaceutical compositions for the treatment of insulin resistance.
NO973489D0 (en) Stabilized gas emulsion containing phospholipid for contrast enhancement in ultrasound examinations
TNSN96072A1 (en) N- (INDOLE -2-CARBONYL) -GLYCINAMIDES SUBSTITUTED, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
FI972287A (en) Novel types of polysubstituted DTPA derivatives and their metal complexes, pharmaceutical substances containing such complexes, their use in diagnosis and therapy, and methods for the preparation of said complexing agents and complexes and methods for their.
TNSN96104A1 (en) (1S, 2S) -1- (4-HYDROXYPHENYL) -2- (4-HYDROXY-4-PHENYLPIPERIDINE-1-YL) -1-PROPANOL TRIHYDRATE METAHENSULFONATE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
DE59609926D1 (en) STABILIZED THYROID HORMONE DRUGS
DE69629413D1 (en) Liquid crystal compound and liquid crystal composition containing it
MA26608A1 (en) PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEART FAILURE.
DZ2521A1 (en) Pharmaceutical compositions comprising 5-Ä4-Ä2- (methyl-n- (2-pyridyl) amino) ethoxyÜbenzylÜ-thiazolidine-2,4-dione and insulin for a method of treatment.
FR2716075B1 (en) A method for enhancing the effectiveness of an agricultural chemical, enhancer and enhancer composition used in this method and agricultural chemical composition comprising this enhancer.
HUP0003629A2 (en) Synergic pharmaceutical composition for the treatment of diabetes containing thiazolidinedione, insulin secretagogue and diguanide
BR0011928A (en) Compound, pharmaceutical composition, use of, a compound and methods for the treatment of diabetic complications, for the treatment or prevention of the development of disease conditions associated with impaired neuronal conduction velocity and diabetic neuropathy
DE69625315D1 (en) Photosensitive silver halide emulsions and process for their preparation
MA24571A1 (en) COMPOSITIONS COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETAGOGUE FOR A TREATMENT METHOD
FR2559668B1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES AND DISEASES AND MALFUNCTIONS OF LIVER
MA26522A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SUGAR DIABETES AND RELATED CONDITIONS.
FR2752422B1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 4-OXO-BUTANOIC ACIDS
HUP0003626A2 (en) Pharmaceutical composition for treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
DE69632697D1 (en) Naphthol compound and liquid crystal composition and liquid crystal element containing this compound
BG102222A (en) The use of derivatives of the sulphaminic acid, acylsulphanomides or sulphamoylcarbamates for the preparation of a medicament for reducing lipoprotein levels
ITRM940776A0 (en) IMAGING APPARATUS FOR OPTICALLY REVEALING THE AMOUNT OF A DEVELOPING AGENT